Abstract
SUMMARYAn economic model was developed to estimate the relative cost‐effectiveness of alternative HMG‐CoA reductase inhibitors (statins) – atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin – to achieve target low‐density lipoprotein cholesterol (LDL‐C) levels in a population of secondary CHD prevention patients. By using a cholesterol target as the endpoint of interest and a dose titration approach, the model assumes that the statins demonstrate a class effect through cholesterol lowering. The model was used to estimate the proportion of patients achieving target LDL‐C levels (<3 mmol/l) under each scenario tested. Total costs and incremental cost‐effectiveness relative to no treatment and to the lowest cost option were estimated for each scenario. Total costs were highest for pravastatin and lowest for cerivastatin. Compared with no treatment, the incremental cost per patient treated to target LDL‐C varied between £383 (atorvastatin) and £1213 (pravastatin). Incremental cost‐effectiveness ratios in comparison with the lowest cost treatment (cerivastatin) were £141 per additional patient achieving target LDL‐C with atorvastatin, and £275 with simvastatin. Fluvastatin and pravastatin were both less effective and more expensive than the lowest cost therapy. Although cerivastatin was associated with lowest expected costs, therapy with atorvastatin achieved the lowest cost‐effectiveness ratios. Hence atorvastatin would allow the largest number of patients to be treated to target LDL‐C within a fixed drug budget. Choosing between drug therapies on the basis of price alone may be misleading if the effectiveness of therapies varies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.